Cure My Disease

Don't miss your cure!

 Log in / Sign up

New HIV pill study: could a simpler 2-drug regimen match a standard 3-drug combo?

NCT ID NCT05979311

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 26, 2026 · Updated 15 times

Summary

This study tests whether a two-drug HIV pill (dolutegravir/lamivudine) works as well as a three-drug pill (bictegravir/emtricitabine/tenofovir alafenamide) for adults who have never taken HIV medication before. About 473 participants will take one of the two pills daily for up to 96 weeks. The main goal is to see if both treatments keep the virus at very low levels in the blood. This is a disease control study, not a cure, because people with HIV need lifelong treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, C1425AWK, Argentina

  • GSK Investigational Site

    Córdoba, X5000JJS, Argentina

  • GSK Investigational Site

    Antwerp, 2000, Belgium

  • GSK Investigational Site

    Brussels, 1000, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

  • GSK Investigational Site

    Hvidovre, 2650, Denmark

  • GSK Investigational Site

    Bordeaux, 33000, France

  • GSK Investigational Site

    Bordeaux, 33076, France

  • GSK Investigational Site

    Lyon, 31059, France

  • GSK Investigational Site

    Montpellier, 34090, France

  • GSK Investigational Site

    Nice, 06202, France

  • GSK Investigational Site

    Nîmes, 30029, France

  • GSK Investigational Site

    Paris, 75012, France

  • GSK Investigational Site

    Paris, 75013, France

  • GSK Investigational Site

    Paris, 75018, France

  • GSK Investigational Site

    Paris, 75970, France

  • GSK Investigational Site

    Berlin, 10787, Germany

  • GSK Investigational Site

    Cologne, 50668, Germany

  • GSK Investigational Site

    Frankfurt, 60590, Germany

  • GSK Investigational Site

    Hamburg, 20146, Germany

  • GSK Investigational Site

    München, 80336, Germany

  • GSK Investigational Site

    Athens, 106 76, Greece

  • GSK Investigational Site

    Athens, 11 527, Greece

  • GSK Investigational Site

    Thessaloniki, 54635, Greece

  • GSK Investigational Site

    Dublin, 7, Ireland

  • GSK Investigational Site

    Dublin, D09 V2N0, Ireland

  • GSK Investigational Site

    Haifa, 31096, Israel

  • GSK Investigational Site

    Ramat Gan, 52621, Israel

  • GSK Investigational Site

    Rehovot, 76100, Israel

  • GSK Investigational Site

    Tel Aviv, 64239, Israel

  • GSK Investigational Site

    Bari, 70124, Italy

  • GSK Investigational Site

    Bergamo, 24127, Italy

  • GSK Investigational Site

    Padova, 35128, Italy

  • GSK Investigational Site

    Pavia, 27100, Italy

  • GSK Investigational Site

    Sassari, 07100, Italy

  • GSK Investigational Site

    Aichi, 460-0001, Japan

  • GSK Investigational Site

    Osaka, 540-0006, Japan

  • GSK Investigational Site

    Tokyo, 108-8639, Japan

  • GSK Investigational Site

    Tokyo, 162-8655, Japan

  • GSK Investigational Site

    Mérida, 97070, Mexico

  • GSK Investigational Site

    Bydgoszcz, 85-030, Poland

  • GSK Investigational Site

    Lodz, 91-347, Poland

  • GSK Investigational Site

    Wroclaw, 50-136, Poland

  • GSK Investigational Site

    Aveiro, 3814-501, Portugal

  • GSK Investigational Site

    Porto, 4099-001, Portugal

  • GSK Investigational Site

    Badalona, 08916, Spain

  • GSK Investigational Site

    Barcelona, 08036, Spain

  • GSK Investigational Site

    Elche Alicante, 03203, Spain

  • GSK Investigational Site

    La Laguna-Tenerife, 35010, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

  • GSK Investigational Site

    Marbella, 29603, Spain

  • GSK Investigational Site

    Palma de Mallorca, 07120, Spain

  • GSK Investigational Site

    Palma de Mallorca, 7198, Spain

  • GSK Investigational Site

    Valencia, 46014, Spain

  • GSK Investigational Site

    Stockholm, SE-14186, Sweden

  • GSK Investigational Site

    Basel, 4031, Switzerland

  • GSK Investigational Site

    Zurich, 8005, Switzerland

  • GSK Investigational Site

    Glasgow, G12 OYN, United Kingdom

  • GSK Investigational Site

    London, E9 6SR, United Kingdom

  • GSK Investigational Site

    London, SE5 8AF, United Kingdom

  • GSK Investigational Site

    London, W1D 6AQ, United Kingdom

  • GSK Investigational Site

    London, W2 1NY, United Kingdom

Conditions

Explore the condition pages connected to this study.

HIV HIV INFECTIONS